aibioAspira Women's Health names interim CEO after Buhle exit
Tickers AWHL
Chairman John Fraser takes over as interim chief executive effective June 17, 2026, while the board searches for a permanent CEO. Terms of Michael Buhle's separation agreement are not yet final.
Key facts
- Company
- Aspira Women's Health Inc. (OTC: AWHL)
- News type
- Company Updates
- Primary source
- Aspira Women's Health Inc. 8-K (2026-06-22)
Aspira Women's Health Inc. said that Michael Buhle ceased serving as chief executive officer on June 17, 2026, and that its board appointed John Fraser, the company's current chairman, to serve as interim chief executive officer effective the same day. The change was reported in a Form 8-K dated June 22, 2026, filed under Item 5.02, which covers departures of officers and the appointment of new ones.
The change
Mr. Fraser also serves as the company's principal executive officer. The board is conducting a search of internal and external candidates for the permanent role, and the filing does not give a timetable for that search.
The filing says Mr. Buhle's departure was not the result of any disagreement with the company on any matter relating to its operations, policies or practices. The company and Mr. Buhle are discussing a separation agreement, but the terms had not been finalized when the 8-K was filed. Aspira said it will amend the report to disclose any further information required by Item 5.02, including the material terms of a separation agreement, within four business days after that information is determined or becomes available.
The new interim chief executive
Mr. Fraser is 66 years old. The filing says he is co-founder and co-portfolio manager of Seamark Capital, which it describes as a fundamentals-based proprietary research growth equities asset management advisor.
The report states that there are no arrangements or understandings between Mr. Fraser and any other person under which he was appointed to his positions, and no family relationships between him and any director or executive officer of the company.
What the company does
Aspira is dedicated to the discovery, development and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. Its commercial portfolio includes OvaWatch, which the company says can be used multiple times to monitor an adnexal mass, and the broader OvaSuite tests, which it describes as historically well adopted by gynecologists and healthcare providers.
Its pipeline covers two areas, endometriosis and ovarian cancer. For endometriosis, the company is developing ENDOinform, a multi-marker test that combines serum proteins, micro RNA and clinical data. In ovarian cancer, its OVAinform program combines serum proteins, miRNA and clinical data to assess the risk of the disease. The annual report puts the addressable market for its tests at between 2 and 4 million tests per year, based on 1.5 million women presenting with an indeterminate adnexal mass.
Financial position
The company's annual report on Form 10-K, filed April 1, 2026, says its current capital resources are not sufficient to fund its operations for the remainder of 2026. It also says the company has been pursuing strategic alternatives and seeking to raise additional capital. The report recounts that the Nasdaq Hearings Panel determined to delist the company's shares, and that the shares began trading on the OTC Markets Group effective at the open of trading on April 17, 2025.
For fiscal 2025 the company reported revenue of $343,000, compared with $4,000 in fiscal 2024. Research and development expense was $2.9 million in 2025, against $3.3 million a year earlier. The net loss was $12.8 million in 2025 and $13.1 million in 2024. Cash from operations was negative $7.0 million in 2025 and negative $12.1 million in 2024. Year-end cash and cash equivalents were $1.8 million at the end of 2024.
What comes next
The filing gives no date for naming a permanent chief executive and no terms for Buhle's separation. The statement that his exit was not the result of a disagreement is the company's own. Its annual report says current capital resources are not sufficient to fund operations for the remainder of 2026. Revenue was $343,000 for 2025 against a net loss of $12.8 million and cash used in operations of $7.0 million. The shares have traded on the OTC Markets since the Nasdaq delisting in April 2025. The interim chief executive is a co-founder of an asset management firm, and the filing says nothing about his plans for the business.